<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02984228</url>
  </required_header>
  <id_info>
    <org_study_id>2015-188</org_study_id>
    <nct_id>NCT02984228</nct_id>
  </id_info>
  <brief_title>Platelet-rich Plasma vs. Hyaluronic Acid for Glenohumeral Osteoarthritis</brief_title>
  <official_title>The Efficacy of Ultrasound Guided Glenohumeral Joint Injections of Platelet Rich Plasma (PRP) Versus Hyaluronic Acid (HA) in the Treatment of Glenohumeral Osteoarthritis: a Randomized, Double-blind Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <brief_summary>
    <textblock>
      This study seeks to expand the current literature in demonstrating potentially efficacious,&#xD;
      conservative treatments in the management of glenohumeral osteoarthritis (OA) and will&#xD;
      compare ultrasound-guided injections of hyaluronic acid vs. platelet-rich plasma. We aim to&#xD;
      obtain information measuring potential benefits of these interventions and to observe for any&#xD;
      adverse events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glenohumeral OA accounts for approximately 2-5% of all chronic shoulder pain and may be&#xD;
      classified into primary and secondary forms. Primary glenohumeral OA is caused by&#xD;
      degenerative joint disease, inflammatory arthropathies, and neuropathic arthropathy secondary&#xD;
      to syringomyelia or diabetes. Secondary glenohumeral OA is caused by trauma, postoperative&#xD;
      changes after arthroscopy or capulorraphy, and osteonecrosis. Hyaluronic acid is found in&#xD;
      synovial joint fluid and has viscoelastic, chondroprotective, and possibly anti-inflammatory&#xD;
      properties. It has been shown to increase joint lubrication. Platelet-rich plasma contains&#xD;
      growth factors that have been shown to promote tissue regeneration. The aim of this study is&#xD;
      to determine whether injections of hyaluronic acid or platelet-rich plasma can be used&#xD;
      reliably to decrease pain, restore function, and improve quality of life in patients&#xD;
      suffering from glenohumeral OA. Patients will be randomized to receive either an injection of&#xD;
      hyaluronic acid or an injection of platelet-rich plasma. Outcomes will be assessed via&#xD;
      questionnaires for up to 52 weeks post-procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">November 2020</completion_date>
  <primary_completion_date type="Actual">November 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Shoulder Pain and Disability Index (SPADI) score</measure>
    <time_frame>Up to 52 weeks post-procedure</time_frame>
    <description>Score ranges from 0-100, with a higher score representing higher disability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Shoulder Function</measure>
    <time_frame>Up to 52 weeks post-procedure</time_frame>
    <description>Shoulder function will be assessed using the American Shoulder and Elbow Surgeons Society Standardized Shoulder Assessment Form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain medication usage</measure>
    <time_frame>Up to 52 weeks post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>Up to 52 weeks post-procedure</time_frame>
    <description>Sleep quality will be assessed on a 0-10 scale, where 0=&quot;I could not sleep at all&quot; and 10=&quot;I slept perfectly well&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>Up to 52 weeks post-procedure</time_frame>
    <description>Satisfaction will be assessed using the North American Spine Society Patient Satisfaction Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Up to 52 weeks post-procedure</time_frame>
    <description>Any complications reported will be collected.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Shoulder Pain</condition>
  <arm_group>
    <arm_group_label>Platelet-rich plasma (PRP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive an injection of PRP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive an injection of hyaluronic acid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRP</intervention_name>
    <arm_group_label>Platelet-rich plasma (PRP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic Acid</intervention_name>
    <arm_group_label>Hyaluronic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <arm_group_label>Hyaluronic Acid</arm_group_label>
    <arm_group_label>Platelet-rich plasma (PRP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  English speaking/literate&#xD;
&#xD;
          -  Age 18-100 years&#xD;
&#xD;
          -  Visual analog score pain &gt;= 5&#xD;
&#xD;
          -  Greater than or equal to 3 months of pain after onset of symptoms that has failed&#xD;
             conservative treatments&#xD;
&#xD;
          -  Confirmation of glenohumeral OA via routine imaging (MRI and x-ray; must be recent and&#xD;
             within the past year)&#xD;
&#xD;
          -  Transient relief of symptoms after diagnostic intra-articular injection into the&#xD;
             glenohumeral joint&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-English speaking/illiterate&#xD;
&#xD;
          -  Painful active, concurrent cervical spine conditions&#xD;
&#xD;
          -  Current non-steroidal anti-inflammatory drug (NSAID) use&#xD;
&#xD;
          -  History of taking coumadin or similar anticoagulant, have a known coagulopathy,&#xD;
             bleeding dyscrasia, or platelet count &lt; 150,000/cubic mm&#xD;
&#xD;
          -  Allergic reaction to poultry or previous viscosupplementation&#xD;
&#xD;
          -  Involved in workers' compensation or active litigation involving affected shoulder&#xD;
&#xD;
          -  Inability to refrain from NSAID use for 5 days prior to and 6 weeks after injection&#xD;
&#xD;
          -  History of corticosteroid injection to affected shoulder within the last 3 months&#xD;
&#xD;
          -  History of viscosupplementation or platelet-rich plasma to affected shoulder within&#xD;
             the last 6 months&#xD;
&#xD;
          -  Presence of acute fracture&#xD;
&#xD;
          -  History of shoulder tumor&#xD;
&#xD;
          -  Known uncontrolled systemic illness (uncontrolled diabetes, human immunodeficiency&#xD;
             virus, vasculitis, autoimmune/inflammatory disease)&#xD;
&#xD;
          -  Psychiatric and somatoform disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Kirschner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 1, 2016</study_first_submitted>
  <study_first_submitted_qc>December 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2016</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Shoulder Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

